Top stock movements in today's session. Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem Jasper shares drop after updated BEACON study shows strong results but faces disruption from compromised drug product lot and halted pipeline programs.
Here are the top movers in Monday's session. Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
What's going on in today's pre-market session Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Russell 2000 Index Forecast As The Crash Continues: Buy The Dip? The Russell 2000 Index has plunged and formed a death cross this year as American stocks sink amid rising worries about Donald Trump’s policies.
Futures Slump As Yields, Dollar Soar In premarket trading Quantum stocks tumbled after Nvidia CEO Jensen Huang said that “very useful” quantum computers are likely decades away.
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? Jasper Therapeutics' SPOTLIGHT study reports 93% clinical response in cold urticaria and symptomatic dermographism. The 120mg dose showed 83% complete response and no severe adverse events. Full data expected by mid-2025.
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q2 2024 JSPR stock results show that Jasper Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024 JSPR stock results show that Jasper Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of FMC Corporation (
NYSE: FMC ) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results.
